Synchronous Bilateral Breast Cancer: Clinical Features, Pathology and Survival Outcomes from a Tertiary Cancer Center
- 26 Downloads
Synchronous bilateral breast cancers (SBBCs) are rare and are defined as occurrence of tumor in the contralateral breast within 6 months of diagnosis of the primary breast tumor. The present study was conducted to look at the clinical and pathological profile and outcomes of patients with SBBC at our center.
Materials and Methods
All SBBC patients treated at our center between 2001 and 2015 were enrolled in the study. Data were retrospectively extracted from the patient case record.
The study included 55 patients with SBBC with a median age of 52 years. Mammographically detected contralateral breast tumor constituted 7% of the cases. The maximum stage in either breast was stage II in 8/55 (15%) patients, stage III in 37/55 (67%) and stage IV in 10/55 (18%). Infiltrating ductal adenocarcinoma (IDC) was the most common pathology and was concordant in both the breasts in 53/55 (96%) patients. Concordance for estrogen receptor (ER), progesterone receptor (PR) and Her2 receptor was seen in 85, 89 and 92%, respectively. The 3-year event-free survival and overall survival for stages II, III and IV were 100, 61 and 0% (P < 0.001) and 100, 64.5 and 0% (P < 0.001), respectively.
SBBC patients at our center present in advanced stage. The maximum stage of either breast tumor determines the outcome. There is heterogeneity in the clinical features, pathological features and survival outcome of SBBC reported from India and rest of the world.
KeywordsSynchronous breast cancer Chemotherapy Radiotherapy Surgery
Compliance with Ethical Standards
The study had no source of funding.
Conflict of interest
None of the authors have any conflict of interest.
The study is retrospective in nature. For this type of study, formal consent and ethical approval are not required. This article does not contain any studies with animals performed by any of the authors.
The study is retrospective in nature and does not require informed consent of individual participants included in the study.
- 10.Patnayak R, Jena A, Rukmangadha N, Chowhan AK, Sambasivaiah K, Phaneendra BV, et al. Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: a tertiary care center experience. Indian J Med Paediatr Oncol. 2015;36:117–22.CrossRefPubMedPubMedCentralGoogle Scholar